1066 pBabe puroL PTEN Citations (11)
Originally described in: PTENUnpublished
Articles Citing 1066 pBabe puroL PTEN
| Articles |
|---|
| A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Fan QW, Cheng CK, Nicolaides TP, Hackett CS, Knight ZA, Shokat KM, Weiss WA. Cancer Res. 2007 Sep 1;67(17):7960-5. PubMed |
| PTEN deletion and heme oxygenase-1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome. Li Y, Su J, DingZhang X, Zhang J, Yoshimoto M, Liu S, Bijian K, Gupta A, Squire JA, Alaoui Jamali MA, Bismar TA. J Pathol. 2011 May;224(1):90-100. doi: 10.1002/path.2855. Epub 2011 Mar 7. PubMed |
| Metformin and erlotinib synergize to inhibit basal breast cancer. Lau YK, Du X, Rayannavar V, Hopkins B, Shaw J, Bessler E, Thomas T, Pires MM, Keniry M, Parsons RE, Cremers S, Szabolcs M, Maurer MA. Oncotarget. 2014 Nov 15;5(21):10503-17. PubMed |
| Recurrent AKT mutations in human cancers: functional consequences and effects on drug sensitivity. Yi KH, Lauring J. Oncotarget. 2016 Jan 26;7(4):4241-51. doi: 10.18632/oncotarget.6648. PubMed |
| Rac1-mediated membrane raft localization of PI3K/p110beta is required for its activation by GPCRs or PTEN loss. Cizmecioglu O, Ni J, Xie S, Zhao JJ, Roberts TM. Elife. 2016 Oct 4;5. pii: e17635. doi: 10.7554/eLife.17635. PubMed |
| PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kalpha Inhibitors in Breast Cancer. Costa C, Wang Y, Ly A, Hosono Y, Murchie E, Walmsley CS, Huynh T, Healy C, Peterson R, Yanase S, Jakubik CT, Henderson LE, Damon LJ, Timonina D, Sanidas I, Pinto CJ, Mino-Kenudson M, Stone JR, Dyson NJ, Ellisen LW, Bardia A, Ebi H, Benes CH, Engelman JA, Juric D. Cancer Discov. 2020 Jan;10(1):72-85. doi: 10.1158/2159-8290.CD-18-0830. Epub 2019 Oct 8. PubMed |
| PTEN and DNA-PK determine sensitivity and recovery in response to WEE1 inhibition in human breast cancer. Brunner A, Suryo Rahmanto A, Johansson H, Franco M, Viiliainen J, Gazi M, Frings O, Fredlund E, Spruck C, Lehtio J, Rantala JK, Larsson LG, Sangfelt O. Elife. 2020 Jul 6;9:e57894. doi: 10.7554/eLife.57894. PubMed |
| Negative cross talk between LIMK2 and PTEN promotes castration resistant prostate cancer pathogenesis in cells and in vivo. Nikhil K, Kamra M, Raza A, Shah K. Cancer Lett. 2021 Feb 1;498:1-18. doi: 10.1016/j.canlet.2020.09.010. Epub 2020 Sep 12. PubMed |
| Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAF(V600E)-Mutant Human Glioma. Schreck KC, Morin A, Zhao G, Allen AN, Flannery P, Glantz M, Green AL, Jones C, Jones KL, Kilburn LB, Nazemi KJ, Samuel D, Sanford B, Solomon DA, Wang J, Pratilas CA, Nicolaides T, Mulcahy Levy JM. Clin Cancer Res. 2021 Nov 15;27(22):6197-6208. doi: 10.1158/1078-0432.CCR-21-2660. Epub 2021 Aug 25. PubMed |
Mammalian Genomic Manipulation with Orthogonal Bxb1 DNA Recombinase Sites for the Functional Characterization of Protein Variants.
Roelle SM, Kamath ND, Matreyek KA.
ACS Synth Biol. 2023 Nov 3. doi: 10.1021/acssynbio.3c00355.
PubMed
Associated Plasmids |
| PTEN protein phosphatase activity regulates metastasis by targeting PKCdelta. Yu Y, Zhao M, Buenaventura RGM, Merlino G. iScience. 2025 May 26;28(6):112741. doi: 10.1016/j.isci.2025.112741. eCollection 2025 Jun 20. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.